Novozymes reported mixed Q4 19 numbers – missing on topline but beating bottomline estimates. Sales came in at DKK 3,731m, up 1% on an organic basis, led by growth in Household. EBIT came in at DKK 922m and management proposed a final dividend of DKK 5.25/share. For FY 20, management expects topline growth of 1-5%, EBIT margin at ~27% and buybacks worth up to DKK 1.5bn. Following the Q4 numbers, we will be tweaking our estimates.
28 Jan 2020
Bioenergy strength not very convincing
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Bioenergy strength not very convincing
Novonesis A/S (Novozymes A/S) Class B (NZYM:WBO) | 0 0 2.6% | Mkt Cap: 80,754m
- Published:
28 Jan 2020 -
Author:
Virendra Chauhan -
Pages:
3
Novozymes reported mixed Q4 19 numbers – missing on topline but beating bottomline estimates. Sales came in at DKK 3,731m, up 1% on an organic basis, led by growth in Household. EBIT came in at DKK 922m and management proposed a final dividend of DKK 5.25/share. For FY 20, management expects topline growth of 1-5%, EBIT margin at ~27% and buybacks worth up to DKK 1.5bn. Following the Q4 numbers, we will be tweaking our estimates.